Authors: Rodby, RA Rohde, RD Clarke, WR Hunsicker, LG Anzalone, DA Atkins, RC Ritz, E Lewis, EJ

Citation: Ra. Rodby et al., The Irbesartan Type II Diabetic Nephropathy Trial: study design and baseline patient characteristics, NEPH DIAL T, 15(4), 2000, pp. 487-497

Authors: Korbet, SM Lewis, EJ Schwartz, MM Reichlin, M Evans, J Rohde, RD

Citation: Sm. Korbet et al., Factors predictive of outcome in severe lupus nephritis, AM J KIDNEY, 35(5), 2000, pp. 904-914

Authors: Lewis, JB Berl, T Bain, RP Rohde, RD Lewis, EJ

Citation: Jb. Lewis et al., Effect of intensive blood pressure control on the course of type 1 diabetic nephropathy, AM J KIDNEY, 34(5), 1999, pp. 809-817

Authors: Wilmer, WA Hebert, LA Lewis, EJ Rohde, RD Whittier, F Cattran, D Levey, AS Lewis, JB Spitalewitz, S Blumenthal, S Bain, RP

Citation: Wa. Wilmer et al., Remission of nephrotic syndrome in type 1 diabetes: Long-term follow-up ofpatients in the captopril study, AM J KIDNEY, 34(2), 1999, pp. 308-314